TEV Stock Overview
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Teva Pharmaceutical Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.10 |
| 52 Week High | US$18.10 |
| 52 Week Low | US$15.85 |
| Beta | 0.88 |
| 11 Month Change | 13.84% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 118.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| TEV | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | 7.7% | -3.6% | 0.7% |
| 1Y | n/a | 6.8% | 12.6% |
Return vs Industry: Insufficient data to determine how TEV performed against the BG Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TEV performed against the BG Market.
Price Volatility
| TEV volatility | |
|---|---|
| TEV Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 4.9% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in BG Market | 7.2% |
| 10% least volatile stocks in BG Market | 2.5% |
Stable Share Price: TEV's share price has been volatile over the past 3 months compared to the BG market.
Volatility Over Time: Insufficient data to determine TEV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 35,737 | Richard Francis | www.tevapharm.com |
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas.
Teva Pharmaceutical Industries Limited Fundamentals Summary
| TEV fundamental statistics | |
|---|---|
| Market cap | €19.81b |
| Earnings (TTM) | -€422.01m |
| Revenue (TTM) | €15.18b |
1.2x
P/S Ratio-43.6x
P/E RatioIs TEV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TEV income statement (TTM) | |
|---|---|
| Revenue | US$16.29b |
| Cost of Revenue | US$8.23b |
| Gross Profit | US$8.06b |
| Other Expenses | US$8.52b |
| Earnings | -US$453.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 49.50% |
| Net Profit Margin | -2.78% |
| Debt/Equity Ratio | 284.0% |
How did TEV perform over the long term?
See historical performance and comparison